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Medicare Supplemental Databases to identify adults with incident PCI (index event)
from 2008-2011. We excluded patients who had less than 12 months of continuous
medical and pharmacy beneﬁts before or after the index procedure; patients were
followed for 12 - 24 months after their index PCI. Baseline characteristics were
deﬁned in the 12-month pre-index period. Clinical outcomes were deﬁned as an
inpatient claim with a principal diagnosis of angina, chest pain, or acute coronary
syndrome (ACS); new angina or chest pain were also deﬁned by presence of an
outpatient claim with an accompanying stress test or repeat PCI. Repeat PCI was
deﬁned as a PCI occurring at least 30 days post-index; PCIs < 30 days post-index
were considered staged procedures.
Results: A total of 51,710 patients met the study criteria (mean age 61.8
[SD¼11.3], 72.4% male). Of these, 33,197 (64.2%) had 24 months of follow-up.
Cumulative incidence of post-index angina or chest pain was 24.8% in the ﬁrst year
and increased to 33.9% by end of year 2. At two years, 4.1% of patients had had an
ACS event. Repeat PCI occurred in 10.8% of patients by one year and 15.1% by
two years.
Conclusions: Persistent or recurrent angina and chest pain remains a signiﬁcant
clinical challenge. Recurrent events, including angina, chest pain, and repeat-PCI,
occurred in approximately one-quarter of patients in the ﬁrst year post-procedure
and increased in the second year of post-procedure follow-up, indicating substantial
burden to patients and payers. Strategies that reduce these adverse events are
needed.
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Background: Previous studies have shown gender impact on clinical outcomes in
patients presenting with coronary artery disease. However, exact role of gender impact
in these studies still have not been fully investigated.
Methods: Gender differences were evaluated in the clinical outcomes of 9,674
patients with coronary artery disease from a large, 55 multicenter, contemporary
percutaneous coronary intervention (PCI) registry enrolled between April 2008
and November 2011 in Korea; the IRIS DES registry. 3,097 women and 6,577
men were followed-up for more than 2 year. The primary end point was rates of
major adverse cardiovascular events (MACE), deﬁned as cardiac death,
myocardial infarction (MI), and target vessel revascularization (TVR) at 2 year
follow-up.
Results: At baseline, women, as compared with men, were older, more frequently had
diabetes, hypertension, and previous congestive heart failure, less frequently had
smoking habits, family history of coronary artery disease, previous MI, and previous
PCI, and had a smaller average stent diameter of the target vessel. The unadjusted
rates of death (3.5% vs 3.3%, P¼0.578), MACE (6.0% vs 6.0%, p¼0.946), and TVR
(1.8% vs1.6%, p¼0.573) were comparable for women and men. MI (1.1% vs 0.9%,
p¼0.494) were similar between men and women. After adjustment for baseline
characteristics in the multivariable analysis, women and men had a similar risk of
MACE rates at 2 year follow up.
Conclusions: Although women had worse baseline characteristics, no differences
in MACE and death were observed between men and women undergoing PCI
with DES.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AngioplasTCT-104
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Background: Although direct stenting with drug-eluting stents (DES) has been
adopted as standard of care, its safety and effectiveness in comparison to the formally
recommended conventional pre-dilatation strategy remains not well established.
Methods: Medline/Pubmed, Cochrane Library, and EMBASE were searched from
2001 to 2014 for studies contrasting Direct DES with conventional pre-dilatation DES
implantation. The primary outcome was major adverse cardiovascular events
(MACE). Secondary outcomes included all-cause death or myocardial infarction (MI),
and target lesion revascularization (TLR). Summarized estimates were obtained using
a random-effects model. Heterogeneity across the studies was assessed through I2.
Results: Overall, 546 potentially relevant citations were screened with 407 excluded
from the title. The remaining 139 abstracts were analyzed resulting in six studies that
met the inclusion criteria enrolling a total of 10,513 participants. Of those, 3909 (37%)
and 6604 (63%) underwent direct DES or pre-dilatation followed by DES implanta-
tion, respectively. Direct DES reduced the likelihood of MACE (odds ratio [OR]: 0.80
95% conﬁdence interval [CI]: 0.70-0.92) with no evidence of heterogeneity of effect
(I2¼ 0%). Additionally, in comparison with pre-dilatation, Direct DES was also
associated with reduced rates of death or MI (OR: 0.74 95% CI [0.60-0.91], I2¼ 0%),
and TLR (OR: 0.60 95% CI [0.41-0.88],I2¼ 14%)(Figure).
Conclusions: Our ﬁndings support the strategy of direct DES for selected patient and
lesion population.TCT-105
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Background: In an effort to harmonize regulatory approval in Japan and Europe we
conducted large, multicentre, randomized CENTURY II clinical trial to assess per-
formance of new sirolimus-eluting stent with bioresorbable polymer (Ultimas-
ter,Terumo Corporation, Tokyo) fully designed and manufactured in Japan. We
compared Ultimaster with Xience DES. The study also addressed regional differences
in percutaneous intervention practice.
Methods: The CENTURY II enrolled 1123 patients in 58 hospitals in Europe, Japan
and Korea. The randomization was stratiﬁed for DES indications in Japan and in this
cohort 724 patients were enrolled. The principal difference from the total population
was exclusion of patients with acute myocardial infarction, left main disease, 3 vessels
disease, ostial lesion, saphenous vein graft, and in-stent restenosis. Primary endpointty Overview and Outcomes B31
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.com(PE) of the study was target lesion failure (TLF) at 9 months. Out of 724 patients, 262
were enrolled in 15 centers in Japan.
Results: There were signiﬁcant differences in almost all baseline patient character-
istics: age (69 vs. 63 years), diabetes mellitus (41% vs. 31%), insulin dependent
diabetes mellitus (1% vs. 24%); acute coronary syndrome (5% vs. 35%), multivessel
disease (30% vs. 46%), in Japan and out of Japan respectively. There were no sig-
niﬁcant differences in lesion characteristics except that more bifurcations (23% vs.
11%; p< 0.01) and longer lesions were treated in Japan (16.7 vs. 15.6 mm: p¼0.02)
with 47% vs. 37% of treated lesions being longer than 20 mm. Radial access was more
frequently used in Japan (86% vs. 70%; p< 0.01). Pre-dilatation was done in 96% of
the lesions in Japan and 73% outside Japan (p< 0.01), while mean number of post
dilatations was 3.83.4 vs. 1.30.6 (p< 0.01) in Japan and outside Japan, res-
pectively. PE up to 4-month was not signiﬁcantly different between the groups (3.4
vs 3.9%).
Conclusions: Despite the signiﬁcant differences observed in several baseline patient
and procedure characteristics, short term results are very similar. One year data,
including results per study stent arm will be presented.
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Background: Clinical outcomes of percutaneous coronary intervention(PCI) for high
age patients has not well investigated in real-world setting.The aim of this study is to
examine clinical outcomes after PCI for high age patients.
Methods: This study was performed as a retrospective registry. Between February
2010 to June 2012, 1646 patients underwent PCI with NoboriTM biolimus-eluting
stent (BES) or everolimus eluting stent(EES). A total of 679 patients were over 75
years old. The main endpoints were major adverse cardiac or cerebrovascular even-
ts(MACE; deﬁned as cardiovascular death, stroke, myocardial infarction), target lesion
revascularization(TLR), target vessel revascularization(TVR), stent thrombosis(ST)
and freedom from any hemorrhagic complication. Mean follow-up was 1.70.7 years.
Results: Baseline characteristics were not signiﬁcantly different between the 2 groups.
At 2-year, the cumulative rate of MACE, TLR, TVR and ST were no signiﬁcant
different between the two groups. The cumulative rate of freedom from any hemor-
rhagic complication was lower in over 75 years old group (91.6% vs 96.1%,
P¼0.0002). After correcting all end points with baseline variables, use of dual anti-
platelet therapy for more than 2 years and use of clopidogrel were independent pre-
dictors for any hemorrhagic complication.Conclusions: We might suggest that use of dual antiplatelet therapy with clopidogrel
for more than 2 years is a risk factor of any hemorrhagic complication for high age
patients.
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Background: Coronary Artery Bypass Graft surgery (CABG) involving Internal
Mammary Artery (IMA) graft is considered superior to stenting for revascularization
of Left Anterior Descending (LAD) artery. Current generation Drug Eluting StentsB32 JACC Vol 64/11/Suppl B j Septemb(DES) are associated with extremely low target vessel revascularization (TVR) rates.
We sought to compare the outcomes of DES versus CABG for treatment of isolated
stenosis of proximal LAD artery.
Methods: PubMed, Cochrane and Web of Science databases were searched for
relevant articles in English language through April 30th 2014 comparing the outcomes
of DES versus CABG for revascularization of isolated proximal LAD stenosis. Out-
comes assessed were all-cause mortality, cardiovascular mortality, myocardial
infarction (MI), peri-procedure stroke and TVR. Study quality, publication bias and
heterogeneity were assessed. Analysis was done using DerSimonian and Laird random
effect model.
Results: From 339 publications, we identiﬁed 4 studies (2 randomized & 2
observational) with 1182 patients (DES¼634 CABG¼548). Mean age was 62 years
and 79% were males in both groups. Follow up period varied from 6 months to 10
years with a mean follow up of 4730 patient-years. DES types used included
Paclitaxel, Sirolimus and Everolimus eluting stents. All CABG surgeries involved
IMA graft while 78% of the CABG were done off-pump using lateral thoracotomy
approach. There was no difference in all-cause mortality (RR: 1.20 95% CI: 0.51-
2.83, p¼0.67), cardiovascular mortality (RR: 0.43 95% CI: 0.11-1.64, p¼0.21), MI
(RR: 0.56 95% CI: 0.20-1.52, p¼0.25) & stroke (RR: 0.55 95% CI: 0.09-3.44,
p¼0.51) rates between DES and CABG. TVR rate was also similar between two
groups (DES Vs CABG RR: 2.20 95% CI: 0.74-649, p¼0.15). Subgroup analysis of
these outcomes both early (< 30days) and late (>30days) after the procedure did
not show any difference between both treatment strategies. Hospital stay however
was signiﬁcantly lower in the DES group as expected (SMD¼ -9.1 days 95% CI:
14.06-4.14, p< 0.001).
Conclusions: DES in comparison to CABG for revascularization of isolated proximal
LAD stenosis is associated with similar outcomes including the TVR rates while the
hospital stay is signiﬁcantly lower.
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Background: The treatment of patients with multi-vessel (MV) disease for percuta-
neous coronary intervention has increased, especially since the introduction of drug
eluting stents, although MV stenting is associated with increased risk of clinical events
compared to patients with single-vessel (SV) treatment. As the appropriate treatment
of which lesions and vessels to stent continues to be investigated, we sought to
evaluate clinical outcomes of MV (2 vessels) stenting with ResoluteTM zotar-
olimus-eluting stent (R-ZES).
Methods: The RESOLUTE global clinical program enrolled 7618 patients treated
with R-ZES. Target Lesion Failure (TLF) is deﬁned as a composite of death from
cardiac causes, target vessel myocardial infarction (TV-MI), and clinically-indicated
target lesion revascularization (TLR). All clinical results in the extended pooled
analysis are calculated using the Kaplan Meier (KM) method. Given differences in
baseline characteristics, patients were matched by propensity scores based on 26
baseline variables and adjusted p-values are provided.
Results: Among 1562 patients treated by MV and 6056 by SV, MV patients had more
complex baseline characteristics than SV patients. At 3 years, TLR (Figure), TLF
(11.0% vs. 9.2%, p¼0.48), cardiac death or TV-MI (6.9% vs 5.8%, p¼0.29), and
ARC deﬁnite/probable stent thrombosis (1.3% vs. 0.9%, p¼0.91) were similar in MV
and SV patients, respectively.
Conclusions: Across the RESOLUTE global clinical program, R-ZES for MV
treatment provided excellent clinical outcomes, with no increased risk as compared
with SV treatment, through long-term follow-up. Submitted on behalf of the RESO-
LUTE Global Clinical Program.er 13–17, 2014 j TCT Abstracts/Angioplasty Overview and Outcomes
